Last checked at 29 Jun 2021 15:15
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
KEY INFORMATIONName of person dealing (Note 1) | Millennium International Management LP |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | US98422L1070 |
Date of dealing | 28th June 2021 |
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 599,475 (0.903%)
| 44,038 (0.066%) | ||||
(2) Derivatives (other than options) | - | - | ||||
(3) Options and agreements to purchase/sell | - | - | ||||
Total | 599,475 (0.903%)
| 44,038 (0.066%) | ||||
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
Ap20
DEALINGS (Note 4)Purchases and sales
Purchase/sale |
Number of relevant securities | Price per unit (Note 5) (USD) |
Purchase | 600 | 4.48 |
Purchase | 800 | 4.48 |
Purchase | 121,243 | 4.48 |
Purchase | 12,631 | 4.48 |
Purchase | 1,529 | 4.48 |
Purchase | 452,986 | 4.48 |
Purchase | 241,251 | 4.48 |
Purchase | 14,025 | 4.48 |
Sale | 505,342 | 4.48 |
Sale | 900 | 4.69 |
Sale | 200 | 4.70 |
Sale | 4,193 | 4.74 |
Sale | 8,000 | 4.68 |
Sale | 250 | 4.67 |
Sale | 1,020 | 4.61 |
Sale | 800 | 4.75 |
Sale | 231 | 4.66 |
Sale | 3,455 | 4.60 |
Sale | 3,928 | 4.63 |
Sale | 6,422 | 4.58 |
Sale | 741 | 4.56 |
Sale | 364 | 4.52 |
Sale | 6,726 | 4.57 |
Sale | 2,242 | 4.59 |
Sale | 1,972 | 4.62 |
Sale | 100 | 4.55 |
Sale | 14,930 | 4.47 |
Sale | 1,000 | 4.53 |
Sale | 4,300 | 4.54 |
Sale | 281 | 4.46 |
Sale | 4,035 | 4.50 |
Purchase | 329 | 4.48 |
Sale | 555,115 | 4.48 |
Sale | 400 | 4.73 |
Sale | 125 | 4.64 |
Sale | 3 | 4.70 |
Sale | 924 | 4.68 |
Sale | 300 | 4.67 |
Sale | 619 | 4.61 |
Sale | 4,384 | 4.60 |
Sale | 26,922 | 4.58 |
Sale | 2,558 | 4.56 |
Sale | 7,929 | 4.52 |
Sale | 2,340 | 4.57 |
Sale | 3,637 | 4.59 |
Sale | 200 | 4.62 |
Sale | 2,658 | 4.55 |
Sale | 900 | 4.49 |
Purchase | 1,461 | 4.47 |
Sale | 2,792 | 4.53 |
Sale | 300 | 4.54 |
Sale | 95 | 4.78 |
Purchase | 60 | 4.46 |
Sale | 2,216 | 4.46 |
Sale | 7,800 | 4.51 |
Sale | 300 | 4.44 |
Purchase | 530 | 4.48 |
Sale | 18,674 | 4.48 |
Purchase | 1 | 4.71 |
Sale | 290 | 4.71 |
Sale | 21 | 4.55 |
Purchase | 14,995 | 4.48 |
Purchase | 15,008 | 4.48 |
Purchase | 15,857 | 4.48 |
Purchase | 177,013 | 4.48 |
Purchase | 3,120 | 4.48 |
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (GBP) (Note 5) |
|
|
|
|
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 29th June 2021 |
Contact name | Milos Naumovic |
Telephone number | +44 203 650 8203 |
If a connected EFM, name of offeree/offeror with which connected |
|
If a connected EFM, state nature of connection (Note 10) |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005621/en/
Copyright Business Wire 2021